—Mkt Cap: —P/E: —
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphala…
Industry Peers
Health Care Technologyloading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value306.88M USD
Revenue (TTM)90.44M USD
Gross Profit73.43M USD
Net Income (TTM)2.70M USD
Revenue/Share2.501 USD
Last Price—
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees156
CountryUS
SectorHealth Care
IndustryHealth Care Technology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-29.87
PEG1.60
EV/EBITDA-232.13
EV/Revenue3.39
P/S4.37
P/B3.50
EPS (TTM)0.01
EPS (Forward)-0.38
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin86.16%
Oper. Margin-6.55%
EBITDA Margin-1.46%
Profit Margin3.17%
ROE2.43%
ROA2.18%
Growth
Revenue Growth26.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF22.52M USD
CapEx (TTM)1.55M USD
FCF Margin21.73%
FCF Yield—
Net Debt-88.39M USD
Net Debt/EBITDA66.86
Balance Sheet
Debt/Equity0.01
Current Ratio11.24
Quick Ratio9.72
Book Value/Sh3.270 USD
Cash/Share2.587 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 24, 2019
Splits
Last Split1:700
Split DateDec 24, 2019
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)21.29 USD
Target Range18.00 USD – 29.76 USD
# Analysts6
Ownership
Shares Out.34.52M
Float28.60M
Insiders8.13%
Institutions48.80%
Short Interest
Short Ratio12.6d
Short % Float11.19%
Short % Out.10.28%
Shares Short3.55M
Short (prev mo.)3.97M
Technical
SMA 5010.34 USD
SMA 20010.20 USD
Beta0.54
S&P 52W Chg28.31%
Avg Vol (30d)—
Avg Vol (10d)507.70K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—